News - BCL6 rearrangement

ELEVATION: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)

P1/2, N=112, Recruiting, Shanghai AbelZeta Ltd. | Phase classification: P1b/2 --> P1/2 | N=72 --> 112 | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Oct 2025

8 days ago

Phase classification • Enrollment change • Trial completion date • Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)

CD20 positive • BCL6 rearrangement • BCL2 rearrangement

prizloncabtagene autoleucel (JNJ-4496)

Localized large B-cell lymphoma with MYC and BCL6 rearrangements as an unexpected finding in an appendectomy specimen. (PubMed, APMIS)

The patient was assigned Stage IEA, IPI = 0 and received chemotherapy. This case depicts a very uncommon occurrence of fully localized LBL in a patient of an unusually young age and clinical presentation for this type of lymphoma.

9 days ago

Journal

BCL6 (B-cell CLL/lymphoma 6)

MYC rearrangement + BCL6 rearrangement • MYC rearrangement • BCL6 rearrangement

10d

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL (clinicaltrials.gov)

P2, N=39, Recruiting, University of Rochester | Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2026

10 days ago

Trial completion date • Trial primary completion date

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq)

11d

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)

P=N/A, N=501, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025

11 days ago

Trial completion date • Trial primary completion date • Minimal residual disease

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement

21d

A Case Report on Carcinomatous Meningitis in a Patient With Double-Hit Lymphoma. (PubMed, Cureus)

Carcinomatous meningitis is a condition in which cancer cells metastasize to the meninges without involving the brain parenchyma; this phenomenon has also been reported in the literature by other terms like "leptomeningeal meningitis," "leptomeningeal carcinomatosis," "leptomeningeal metastasis," or "neoplastic meningitis." This form of CNS involvement has been described as an infrequent complication with the trajectory of this aggressive lymphoma. We report an illuminating case of a 63-year-old male diagnosed with double-hit lymphoma, which was complicated by fatal carcinomatous meningitis.

21 days ago

Journal

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement

25d

The high-grade B-cell lymphomas: Double hit and more. (PubMed, Blood)

The rare, but difficult, diagnostic classification HGBL (NOS) remains a diagnosis of exclusion with limited data on an optimal clinical approach. The days of talking loosely of double and triple hit lymphoma are numbered as this review synergises the current data on biology, prognosis, and therapies in HGBL.

25 days ago

Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement • BCL6 translocation

30d

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma (clinicaltrials.gov)

P2, N=24, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting

30 days ago

Enrollment closed • CAR T-Cell Therapy

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)

BCL6 rearrangement • BCL2 rearrangement

Brukinsa (zanubrutinib)

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma (clinicaltrials.gov)

P2, N=32, Recruiting, Dipenkumar Modi | Trial completion date: Jun 2025 --> Nov 2028 | Trial primary completion date: Sep 2024 --> Nov 2027

1 month ago

Trial completion date • Trial primary completion date

ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)

ALK positive • BCL6 rearrangement • BCL2 rearrangement

cisplatin • gemcitabine • dexamethasone • Epkinly (epcoritamab-bysp)

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes. (PubMed, Blood Cancer J)

No abstract available

1 month ago

Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL. (PubMed, Hemasphere)

However, we observed a subgroup of patients classified as BN2, both in localized and disseminated TLBCL, suggesting a degree of genetic heterogeneity in the TLBCL genetic profile. TLBCL has a distinctive genetic profile similar to PCNSL, supporting its recognition as a separate entity from DLBCL and might provide information to devise targeted therapeutic approaches.

1 month ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • ETV6 (ETS Variant Transcription Factor 6) • CD79B (CD79b Molecule) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • EP300 (E1A binding protein p300) • PIM1 (Pim-1 Proto-Oncogene) • NODAL (Nodal Growth Differentiation Factor) • TBL1XR1 (TBL1X Receptor 1)

CDKN2A deletion • MYD88 L265P • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • ETV6 mutation

VERLen: Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older (clinicaltrials.gov)

P2, N=71, Active, not recruiting, The Lymphoma Academic Research Organisation | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed

BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Monjuvi (tafasitamab-cxix)

CYTB323A12101: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (clinicaltrials.gov)

P1/2, N=225, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> May 2028

1 month ago

Trial completion date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

CD19 positive • BCL6 rearrangement • BCL2 rearrangement

Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)

ZUMA-24: Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (clinicaltrials.gov)

P2, N=30, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Mar 2026 --> Sep 2024

1 month ago

Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV

POLARIX: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)

P3, N=1000, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2026

1 month ago

Trial completion date • Trial primary completion date • Combination therapy

ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)

ALK positive • CD20 positive • BCL6 rearrangement

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq)

2ms

Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma. (PubMed, Blood Cancer J)

Two cases, which transformed from marginal zone lymphomas, carried mutations in KLF2, TNFAIP3 and KMT2D. These findings expand the spectrum of tumors carrying CCND1 rearrangement that may occur as a secondary event in DLBCL mediated by aberrant CSR/SHM and associated with a mutational profile different from that of MCL.

2 months ago

Journal

CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • KMT2D (Lysine Methyltransferase 2D) • TNFAIP3 (TNF Alpha Induced Protein 3) • SOX11 (SRY-Box Transcription Factor 11)

BCL6 rearrangement

2ms

CD38, CD39, and BCL2 differentiate disseminated forms of high-grade B-cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B-cell lymphoma. (PubMed, Cytometry B Clin Cytom)

We finally confirmed the utility of the scoring system previously proposed by Khanlari to distinguish HGBCL cells from B lymphoblasts of B-ALL. In conclusion, we described a distinct immunophenotypic portrait of HGBCL cells and proposed a strategy to differentiate these cells from other aggressive B lymphoma entities in biological samples.

2 months ago

Journal • IO biomarker

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD38 (CD38 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)

MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement

2ms

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov)

P2, N=60, Recruiting, Juventas Cell Therapy Ltd. | Trial primary completion date: Jun 2024 --> Dec 2024

2 months ago

Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

CD19 positive • BCL6 rearrangement • BCL2 rearrangement • CD20 negative

cyclophosphamide • Yuanruida (inaticabtagene autoleucel)

2ms

TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)

P2, N=41, Recruiting, Mayo Clinic | N=62 --> 41

2 months ago

Enrollment change • Combination therapy

PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)

ALK positive • BCL6 rearrangement • BCL2 rearrangement

Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)

6ms

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)

P1, N=24, Completed, Juno Therapeutics, a Subsidiary of Celgene | Active, not recruiting --> Completed | N=80 --> 24 | Trial completion date: Jun 2024 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024

6 months ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

cyclophosphamide • BMS-986353

6ms

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)

P2, N=27, Active, not recruiting, Takeda | N=265 --> 27 | Recruiting --> Active, not recruiting

6 months ago

Enrollment closed • Enrollment change

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

cyclophosphamide • TAK-007

7ms

Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study. (PubMed, Blood)

Furthermore, because one IGH allele is already disrupted by the existing BCL2 rearrangement, the MYC rearrangement architecture in HGBCL-DH-BCL2 likely reflects selective pressure to preserve both BCL2 and B cell receptor expression. These data provide new mechanistic explanations for the distinct patterns of MYC rearrangements observed across different lymphoma entities.

7 months ago

Journal • IO biomarker

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

MYC rearrangement + BCL2 rearrangement • MYC rearrangement + BCL6 rearrangement • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement

7ms

MPCT-012L: Study of IMPT-314 in R/R Aggressive B-cell NHL (clinicaltrials.gov)

P1/2, N=150, Recruiting, ImmPACT Bio | N=100 --> 150

7 months ago

Enrollment change

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

IMPT-314

7ms

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (clinicaltrials.gov)

P=N/A, N=241, Active, not recruiting, Duke University | Phase classification: P2 --> P=N/A

7 months ago

Phase classification

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

7ms

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov)

P2/3, N=422, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026

7 months ago

Trial completion date • Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)

BCL6 rearrangement • BCL2 rearrangement

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Onureg (azacitidine oral) • Mabtas (rituximab biosimilar)

7ms

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL (clinicaltrials.gov)

P1, N=47, Active, not recruiting, Sanofi | Trial completion date: Apr 2024 --> Aug 2024

7 months ago

Trial completion date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

SAR442257

7ms

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P1, N=55, Terminated, Fred Hutchinson Cancer Center | Active, not recruiting --> Terminated; Terminated due to slow enrollment and end of funding

7 months ago

Trial termination • CAR T-Cell Therapy

BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • CD4 (CD4 Molecule) • SELL (Selectin L)

CD19 positive • CD8 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative • CD4 expression

cyclophosphamide • fludarabine IV • JCAR014

7ms

ZUMA-24: Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (clinicaltrials.gov)

P2, N=35, Active, not recruiting, Kite, A Gilead Company | Recruiting --> Active, not recruiting

7 months ago

Enrollment closed

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV

7ms

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (clinicaltrials.gov)

P2, N=27, Recruiting, Patrick C. Johnson, MD | Not yet recruiting --> Recruiting | Trial completion date: Sep 2029 --> Mar 2029 | Trial primary completion date: Sep 2024 --> Mar 2025

7 months ago

Enrollment open • Trial completion date • Trial primary completion date • Combination therapy

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

cyclophosphamide • Calquence (acalabrutinib) • Breyanzi (lisocabtagene maraleucel) • fludarabine IV

8ms

Cytogenetic and pathologic characterization of MYC-rearranged B-cell lymphomas in pediatric and young adult patients. (PubMed, J Hematop)

The pediatric to YA transition is characterized by decreasing frequency in BL and increasing genetic heterogeneity of MYC-R BCL, with emergence of DH-BCL with MYC and BCL6-R. FISH to evaluate for BCL2 and BCL6 rearrangements is likely not warranted in the pediatric population but should continue to be applied in YA BCL.

8 months ago

Journal

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

8ms

CRC-403: A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov)

P1/2, N=50, Recruiting, 2seventy bio | Trial primary completion date: Dec 2023 --> Aug 2024

8 months ago

Trial primary completion date • CAR T-Cell Therapy

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

bbT369

8ms

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy (clinicaltrials.gov)

P1, N=14, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=30 --> 14 | Trial completion date: Oct 2025 --> Mar 2025 | Trial primary completion date: Oct 2025 --> Mar 2024

8 months ago

Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy

ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

Copiktra (duvelisib) • Onureg (azacitidine oral)

8ms

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (clinicaltrials.gov)

P2, N=49, Recruiting, Barbara Ann Karmanos Cancer Institute | Trial completion date: Nov 2023 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2025

8 months ago

Trial completion date • Trial primary completion date • Combination therapy

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • methylprednisolone sodium succinate

8ms

Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (clinicaltrials.gov)

P1/2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

8 months ago

Trial completion date • Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)

CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative

cyclophosphamide • fludarabine IV

8ms

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)

P1/2, N=80, Not yet recruiting, Juventas Cell Therapy Ltd. | Initiation date: Oct 2023 --> Aug 2024

8 months ago

Trial initiation date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • CD22 (CD22 Molecule)

CD19 positive • BCL6 rearrangement • BCL2 rearrangement

cyclophosphamide • HY004

8ms

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) (clinicaltrials.gov)

P2, N=40, Not yet recruiting, University Health Network, Toronto | Initiation date: Dec 2023 --> Aug 2024

8 months ago

Trial initiation date • Circulating tumor DNA • FDG PET

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement

doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)

8ms

Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement. (PubMed, Virchows Arch)

In conclusion, both BCL6-R-positive FL and BCL6-R-positive DLBCL had a common mutational profile; but also, differences. DLBCL cases had a higher density of microenvironment markers.

8 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • CD163 (CD163 Molecule) • ARID1B (AT-Rich Interaction Domain 1B) • CD36 (thrombospondin receptor) • IL10 (Interleukin 10) • RHOA (Ras homolog family member A) • PIM1 (Pim-1 Proto-Oncogene) • CSF1R (Colony stimulating factor 1 receptor) • HLA-B (Major Histocompatibility Complex, Class I, B) • H1-4 (H1.4 Linker Histone, Cluster Member) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BTG2 (BTG Anti-Proliferation Factor 2) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)

ATM mutation • MYD88 L265P • BCL6 rearrangement • ARID1B mutation • IL10-L • PIM1 mutation • MYC negative

8ms

ZUMA-7: Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov)

P3, N=359, Active, not recruiting, Kite, A Gilead Company | Trial completion date: Jan 2035 --> Oct 2024

8 months ago

Trial completion date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement • CD20 negative

carboplatin • cytarabine • cyclophosphamide • oxaliplatin • Yescarta (axicabtagene ciloleucel) • fludarabine IV • methylprednisolone sodium succinate

8ms

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov)

P2, N=60, Recruiting, Juventas Cell Therapy Ltd. | Trial primary completion date: Dec 2023 --> Jun 2024

8 months ago

Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

CD19 positive • BCL6 rearrangement • BCL2 rearrangement • CD20 negative

cyclophosphamide • Yuanruida (inaticabtagene autoleucel)

9ms

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)

P2, N=265, Recruiting, Takeda | Trial completion date: Oct 2029 --> Jun 2030 | Trial primary completion date: Oct 2029 --> Oct 2025

9 months ago

Trial completion date • Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

cyclophosphamide • TAK-007

9ms

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (clinicaltrials.gov)

P1/2, N=44, Recruiting, Leland Metheny | Trial completion date: Jun 2025 --> May 2026 | Trial primary completion date: Dec 2023 --> May 2024

9 months ago

Trial completion date • Trial primary completion date • Post-transplantation

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)

BCL6 rearrangement • CD22 positive • BCL2 rearrangement

Besponsa (inotuzumab ozogamicin)

9ms

Do Double-Expressor High-Grade B-Cell Lymphomas Really Need Intensified Treatment? A Report from the Real-Life Series of High-Grade B-Cell Lymphomas Treated with Different Therapeutic Protocols at the Institute of Oncology Ljubljana. (PubMed, Biomedicines)

In total, 169 patients were treated with R-CHOP, 10 with R-CHOP and intermediate-dose methotrexate, 19 with R-DA-EPOCH, and 16 with other regimens. The 5-year OS for DHL patients was 32.4% (95% CI 16.6-48.2%) while all three TH patients were deceased or lost to follow-up. Our analyses of real-life data disclose that the R-CHOP protocol with CNS prophylaxis is a successful and curative treatment for a substantial proportion of DEL patients.

9 months ago

Journal • IO biomarker

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

MYC rearrangement + BCL2 rearrangement • MYC overexpression • MYC overexpression + BCL2 overexpression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement

Rituxan (rituximab) • methotrexate

9ms

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL (clinicaltrials.gov)

P1, N=47, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Apr 2024

9 months ago

Enrollment closed • Trial completion date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

BCL6 rearrangement • BCL2 rearrangement

SAR442257